News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche Says MabThera Gets Positive Phase III Data
October 26, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Oct 26 (Reuters) - Lymph cancer treatment MabThera has been shown to work as a maintenance therapy in patients with relapsed indolent non-Hodgkin's lymphoma, according to initial details from a Phase III study released by Roche on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
Roche
MORE ON THIS TOPIC
Drug Development
CRO Boom in APAC region, With China at the Forefront
November 19, 2025
·
5 min read
·
Jennifer Smith-Parker
Podcast
Billions More in M&A, Another Bidding War and More FDA Drama
November 19, 2025
·
1 min read
·
Heather McKenzie
Career Advice
Science Isn’t Complete Until It’s Clear: Communication Key to Research Process
November 19, 2025
·
5 min read
·
Manali Shah
Cardiovascular disease
Merck Extends Winrevair’s Win Streak With New Mid-Stage Data in Type of Hypertension
November 18, 2025
·
2 min read
·
Tristan Manalac
